Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.
Sanofi's CEO prioritizes rebuilding Regeneron partnership while canceling amlitelimab and itepekimab programs ahead of Dupixent's patent cliff. The shift from internal R&D to M&A and partnerships reflects pharma consolidation under IP pressure.
An article from
News roundup
Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.
Published July 31, 2026
Getty Images
Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
Booming Dupixent sales fuel Regeneron's biggest quarter since pandemic
Takeda, Regeneron, Sanofi and Bristol Myers trim pipelines
Lilly, Resilience commit $750M to boost US diabetes, obesity med production
